Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study - Institut Pasteur Access content directly
Journal Articles Influenza and Other Respiratory Viruses Year : 2023

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study

1 EpiConcept [Paris]
2 Institute of Health Carlos III
3 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
4 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
5 RKI - Robert Koch Institute [Berlin]
6 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
7 HSE - Health Service Executive [Dublin]
8 RIVM - National Institute for Public Health and the Environment [Bilthoven]
9 University of Kalmar
10 CIPH - Croatian Institute of Public Health [Zagreb]
11 Cantacuzino Institute [Romania]
12 GMV-ARN (UMR_3569 / U-Pasteur_2) - Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses
13 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
14 Dirección General de Salud Pública
15 Public Health Agency of Sweden
16 INSA - Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal]
17 Cantacuzino National Medico-Military Institute for Research Development [Bucharest]
18 Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli]
19 UCD - University College Dublin [Dublin]
20 School of Social Sciences. Campus de Melilla. Univeristy of Granada
21 NIVEL - Netherlands Institute for Health Services Research [Utrecht]
22 ECDC - European Centre for Disease Prevention and Control [Stockholm, Sweden]
Esther Kissling
  • Function : Correspondent author
  • PersonId : 1089378

Connectez-vous pour contacter l'auteur
Lisa Domegan
Clara Mazagatos
Ausenda Machado
Ralf Dürrwald
Marine Maurel
  • Function : Author
Marta Valenciano
I-Move Study
  • Function : Author

Abstract

Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza.
Fichier principal
Vignette du fichier
Influenza Resp Viruses - 2022 - Kissling - Influenza vaccine effectiveness against influenza A subtypes in Europe Results.pdf (1.24 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

pasteur-04097905 , version 1 (15-05-2023)

Licence

Attribution

Identifiers

Cite

Esther Kissling, Francisco Pozo, Iván Martínez-Baz, Silke Buda, Ana‐maria Vilcu, et al.. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study. Influenza and Other Respiratory Viruses, 2023, 17 (1), pp.e13069. ⟨10.1111/irv.13069⟩. ⟨pasteur-04097905⟩
16 View
42 Download

Altmetric

Share

Gmail Facebook X LinkedIn More